SCP Vitalife

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

Sensible Medical Innovation Ltd, founded in 2007 and based in Netanya, Israel, specializes in medical radar monitoring and imaging technology. The company's primary offering, ReDS, is designed to monitor and manage lung fluid in patients with heart failure and other fluid-related conditions. This noninvasive system provides accurate and actionable data that aids physicians in assessing the clinical status of heart failure patients. By enhancing treatment quality and potentially reducing hospital readmissions, Sensible Medical addresses significant challenges in managing chronic medical conditions, contributing to improved patient outcomes and alleviating pressures on healthcare systems worldwide.

ReWalk Robotics Ltd. is a medical device company that specializes in the design, development, and commercialization of robotic exoskeletons aimed at individuals with mobility impairments. The company offers two primary products: the ReWalk Personal System, which supports everyday use for paraplegic individuals in various environments, including homes and workplaces, and the ReWalk Rehabilitation System, designed for therapeutic use in hospitals and rehabilitation centers. These systems enable users to walk, stand, sit, and navigate stairs, enhancing their quality of life. Additionally, ReWalk Robotics is developing ReWalk Restore, a soft suit exoskeleton intended for the rehabilitation of stroke patients. The company markets its products directly to healthcare providers and individuals, as well as through third-party distributors. Founded in 2001, ReWalk Robotics is headquartered in Yokneam Ilit, Israel, with operational facilities in Marlborough, Massachusetts.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.

novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

Beta-O2 Technologies Ltd. is a biomedical company based in Rosh HaAyin, Israel, established in 2004. The company specializes in the development of innovative implantable bioreactors, particularly the ßAir Bio-artificial Pancreas, aimed at treating type 1 diabetes (T1D). This device addresses significant challenges associated with islet transplantation, such as the need for lifelong immunosuppressive therapy and the deterioration of islet functionality due to inadequate oxygen supply. The ßAir device is designed for minimally invasive implantation and aims to provide patients with essential pancreatic hormones in the correct ratio, effectively reducing reliance on insulin injections and minimizing the risk of hypoglycemic episodes. Additionally, the bioreactor offers robust protection from the host immune system, thus eliminating the need for immunosuppressive drugs and preventing potential fatal immune reactions to transplanted cells. Beta-O2 Technologies is also working on the ßAir Bio-artificial Adrenal for treating adrenal insufficiency and stress-related disorders.

GeneGrafts Ltd., also known as GreenGrafts Ltd., is a biotechnology company based in Haifa, Israel, that specializes in developing therapeutic products for cardiac arrhythmia, Parkinson's disease, and epilepsy. Founded in November 2003, the company focuses on proprietary technology for modulating excitable tissues through cell therapy. GeneGrafts has created an innovative platform that utilizes cell grafts derived from the patient's own body, which define ion channels that influence the electrical properties of targeted organs. This approach allows for the functional and structural integration of grafted cells with the target organ, enabling predetermined modulation of its electrical properties. The company's technology aims to offer new treatment options for various neurological disorders and cardiac conditions.

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.